EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--NeoChord, a medical device company focused on minimally invasive mitral valve repair, announced today that it has completed enrollment for its ongoing ‘TACT’ (Transapical Artificial Chordae Tendinae) clinical trial in Europe.
